Multimodal Fusion Artificial Intelligence Model to Predict Risk for Cardiovascular Adverse Events and Myocarditis in Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy
2024

Using AI to Predict Heart Risks in Cancer Patients

Sample size: 2258 publication Evidence: moderate

Author Information

Author(s): Sun Christopher L.F.

Primary Institution: University of Ottawa Heart Institute

Hypothesis

Can a multimodal AI model effectively predict cardiovascular risks in cancer patients receiving immune checkpoint inhibitors?

Conclusion

The study developed a multimodal AI model that improves the prediction of cardiovascular events in cancer patients undergoing immune checkpoint inhibitor therapy.

Supporting Evidence

  • The model achieved an AUC of 0.717, indicating good predictive performance.
  • 11.7% of patients experienced cardiovascular adverse events, with 3% developing myocarditis.
  • The model outperformed single-modality approaches, which had AUCs of 0.59-0.645.
  • The inclusion of echocardiography data did not improve model performance.

Takeaway

Doctors can use a new AI tool to better predict heart problems in cancer patients getting certain treatments, helping them take better care of their patients.

Methodology

The study used a multimodal deep learning model that integrates ECG data and electronic medical records to predict cardiovascular risks.

Potential Biases

The performance of predictive models is highly dependent on the quality and completeness of input data.

Limitations

The model's ability to inform targeted interventions for individual patients is reduced due to the rarity of specific events like myocarditis.

Participant Demographics

Patients receiving immune checkpoint inhibitor therapy at three academic institutions in the United States.

Statistical Information

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1016/j.jacadv.2024.101433

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication